A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028.
J Thorac Oncol. 2019.
PMID: 31668326
No abstract available.